Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
- 23 November 2017
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 13 (3), 367-376
- https://doi.org/10.1016/j.jtho.2017.11.112
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationNature Reviews Clinical Oncology, 2016
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non‐Small Cell Lung Cancer Whose Tumors Express Programmed Death‐Ligand 1The Oncologist, 2016
- A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC StudyClinical Lung Cancer, 2016
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based ChemotherapyThe Oncologist, 2016
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002